The significance of free light-chain ratio in light-chain monoclonal gammopathy of undetermined significance: a flow cytometry sub-study of the iStopMM screening study
Light-chain (LC) monoclonal gammopathy of undetermined significance (MGUS) is a precursor of multiple myeloma (MM) and related conditions. LC-MGUS is characterized by free light-chain (FLC) levels outside defined reference intervals, indirectly indicating underlying plasma cell (PC) monoclonality. Next-generation flow cytometry (NGF) was used to evaluate clonal PC presence in bone marrow (BM) samples from individuals with LC-MGUS in the iStopMM study, aiming to assess the predictive value of the FLC ratio for clonal PC presence and its prognostic implications. BM samples from 61 individuals with LC monoclonal gammopathy were analyzed. Clonal plasma cells were detected in 53.6% of LC-MGUS samples (n = 28) and in all samples from individuals with more advanced conditions (n = 33). The FLC ratio was predictive of clonal PC presence for kappa-involved FLC ratios (p < 0.05; n = 42), with an optimal cutoff of 3.15 (96.7% sensitivity, 91.7% specificity). Of 195 individuals with kappa-involved LC-MGUS in follow-up within the iStopMM study, none with FLC ratios >1.65 to 3.15 progressed to MM (n = 124), whereas 4/71 (5.6%) with FLC ratios >3.15 progressed over median follow-up of 55 months. These findings support using a kappa-involved FLC ratio cutoff of >3.15 to more accurately identify individuals at increased risk of developing symptomatic PC disorders.
Authors
- Sigurður Y. Kristinsson (ORCID: https://orcid.org/0000-0002-4964-7476)
- Róbert Pálmason
- Elías Eyþórsson (ORCID: https://orcid.org/0000-0002-0277-7628)
- Páll T. Önundarson (ORCID: https://orcid.org/0000-0002-5342-9148)
- Brynjar Viðarsson
- Jón Þórir Óskarsson (ORCID: https://orcid.org/0000-0002-9201-1166)
- Brian G.M. Durie (ORCID: https://orcid.org/0000-0002-9883-3769)
- Þórir Einarsson Long (ORCID: https://orcid.org/0000-0003-2377-7886)
- Margrét Sigurðardóttir (ORCID: https://orcid.org/0000-0001-8719-0430)
- Ingunn Þorsteinsdóttir
- Andri Ólafsson (ORCID: https://orcid.org/0000-0002-7381-8431)
- Ísleifur Ólafsson (ORCID: https://orcid.org/0000-0002-3921-5805)
- Bjarni A. Agnarsson (ORCID: https://orcid.org/0000-0001-7721-9965)
- Sigrún Þorsteinsdóttir (ORCID: https://orcid.org/0000-0001-5017-3530)
- Sæmundur Rögnvaldsson (ORCID: https://orcid.org/0000-0003-2162-8414)
- Þorvarður Jón Löve (ORCID: https://orcid.org/0000-0002-2680-6120)
- Ásbjörn Jónsson (ORCID: https://orcid.org/0000-0002-2374-9773)
- Stephen J. Harding
Institutions
- Reykjavík University (IS)
- Cedars-Sinai Medical Center (US)
- University of Iceland (IS)
- Rigshospitalet (DK)
- Akureyri Hospital (IS)
- National University Hospital of Iceland (IS)
- Skåne University Hospital (SE)
Publication Details
- Journal
- Blood Cancer Journal
- Published
- 2024-12-18
- DOI
- https://doi.org/10.1038/s41408-024-01201-9
- Citations
- 5
- Primary Topic
- Multiple Myeloma Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 2.27
Funders
- International Myeloma Foundation
- European Commission
- Icelandic Centre for Research
- Háskóli Íslands
- Horizon 2020 Framework Programme